A coronavirus vaccine developed by US pharmaceutical company Novavax has been approved for conditional sale in Europe. In a clinical trial on adults 18 years of age and older, it was estimated that the effectiveness of preventing the corona virus reached 90%.

Correspondent Kim Jung-woo.

<Reporter> The

European Commission has approved the conditional sale of a COVID-19 vaccine developed by US pharmaceutical company Novavax.

The recombinant protein-based Novavax vaccine becomes the fifth vaccine approved for use in 27 EU member states, following Pfizer, Moderna, AstraZeneca, and Johnson & Johnson.

Earlier, the European Medicines Agency announced that in clinical trials conducted on 45,000 people in the United States, Mexico and the United Kingdom, the effectiveness of Novavax vaccine in preventing COVID-19 was estimated to reach 90%.

He then recommended that the vaccine be approved for use in adults 18 years of age or older if it meets EU standards in terms of efficacy, safety and quality.

[Stanley Erck/CEO of Novavax: We plan to import Novavax vaccine to Europe in January next year, and we can produce 200 million doses of Novavax vaccine during the first quarter.]

However, the European Medicines Agency is Data on the effectiveness of prevention against this disease are still limited.

In the midst of this, American pharmaceutical company Moderna said that booster shot, that is, the third booster vaccination with its vaccine, is effective against omicron mutation.

According to Bloomberg News, Moderna announced that "Analysis of the serum of 20 booster shot recipients showed that the neutralizing antibody in response to the omicron mutation was increased by 37 times."

Currently, Moderna is also developing a vaccine for Omicron, which is expected to enter clinical trials as early as next year.